|
Ondine Biomedical Inc on Monday announced an update on its Lantern phase 3 pivotal study evaluating the company’s non-antibiotic nasal photodisinfection technology, branded Steriwave outside the US. The Vancouver-based antimicrobial therapies developer said endpoint adjudication has been completed, all queries resolved, and site principal investigators are signing all case books, a required administrative step towards database lock. This is expected to complete within the coming week, and once complete, the locked dataset will be transferred to statistical analysis in accordance with the statistical analysis plan. Ondine expects to report top-line results within one to two weeks thereafter. The Lantern study is designed to evaluate the safety and efficacy of Ondine’s nasal photodisinfection technology in reducing the rate of surgical site infections. Conducted in collaboration with HCA Healthcare and select Canadian hospitals, the study enrolled 5,188 patients across 14 HCA Healthcare hospitals in the US and four sites in Canada. Shares in Ondine Biomedical were up 1.1% at 14.67 pence each in London on Monday. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
